PCI Pharma Services (PCI), a pharma and biopharmaceutical global outsourcing provider, has expanded its global clinical footprint with the expansion of cold chain clinical supply storage and distribution capabilities at its Berlin site, providing global access to regional customers. The Berlin facility recently passed regulatory inspection for these expansions and is now fully operational.
 
The company added significant capacity and several new cold chain storage conditions to its capabilities, which now include temperatures from controlled room temperature to -80°C. PCI has doubled the size of its 2-8°C storage and added -20°C and -80°C. The company will also be adding liquid nitrogen storage capabilities at the Berlin site in phase two of the expansion, set to begin in 2022.
 
The Berlin facility is helping PCI support the vaccine supply chain and keep pace with growing demands for biologic therapies. The added capacity is positioned to service small-to-medium sized pharmaceutical companies within Europe, which are conducting clinical trials in the EU, as well as in North America and other parts of the world.
 
“We look forward to welcoming clients to use the newest expansion in our network, part of a larger strategy to ensure that we have capacity to meet the needs of the clinical market as it evolves,” said Brian Keesee, vice president and general manager, Global Clinical Operations and Supply, PCI Pharma Services. “These expanded capabilities and breadth of offerings will ensure that our global and mainland EU customers conducting clinical trials, particularly those in the DACH region of Austria, Germany, and Switzerland, have the support of a full-service solution, which the industry prefers, in a prime location with excellent transport hubs.”
 
This is the latest in series of global clinical expansions across four other sites, including San Diego; Rockford, Illinois; Bridgend, U.K.; and Australia. PCI completed a new Clinical Center of Excellence at its Berlin location in July 2020, following the acquisition of Bellwyck Pharma Services in early 2020.